Rucci Nadia - Modelli biotecnologici sperimentali I

DISCAB
SCHEDA DOCENTE - A.A. 2013-2014
Rucci Nadia
COGNOME E NOME
Ricercatore non confermato
QUALIFICA
BIO17
SSD
Laurea Magistrale in Biotecnologie Mediche
CORSO DI STUDIO
Modelli Biotecnologici Sperimentali I
INSEGNAMENTO
Venerdì h 15-16
ORARIO DI RICEVIMENTO
Stanza B3-37
SEDE PER IL RICEVIMENTO
N. TELEFONO (INTERNO)
[email protected]
E-MAIL
PROGRAMMA DEL CORSO (sintetico)
Il corso prevede l’acquisizione di conoscenze relative ai modelli animali sperimentali
impiegati per studiare i meccanismi molecolari alla base dell’insorgenza di
specifiche patologie. Saranno illustrati i principali modelli animali attualmente
disponibili per studiare le seguenti patologie: infiammazione, malattie croniche
intestinali, aterosclerosi, diabete, patologie dello scheletro, patologie
neurodegenerative, patologie oncologiche.
MATERIALE DIDATTICO
Specifiche pubblicazioni su riviste internazionali consigliate dal docente.
Testo di patologia generale: Robbins e Cotran: “Le basi patologiche delle malattie”
MODALITA’ DI VERIFICA
Esame orale
Allegato 1 – Curriculum scientifico ed elenco pubblicazioni
Dr Nadia Rucci, PhD
Department of Biotechnological and Applied Clinical Sciences
University of L’Aquila , 67100 L’Aquila, Italy
Date of Birth and Place: October 23, 1968, Montbéliard, France.
Education/ Training/ Positions: 1994: Bachelor in Biology, University of Rome “La
Sapienza”, Italy; 1999: PhD in Endocrinology and Metabolic Diseases, University of L’Aquila,
Italy; 2000: Fellowship Adriano Buzzati Traverso Foundation, Bone Biopathology Laboratory
(BBL), Department of Experimental Medicine, University of L’Aquila; 1999-2003: School of
Specialization in Clinical Pathology, University of L’Aquila; 2003-2011: Post-Doctoral
research assistant, BBL, Department of Experimental Medicine, University of L’Aquila; 2011present: Assistant Professor, BBL, Department of Biotechnological and Applied Clinical
Sciences, University of L’Aquila.
Current Research: Bone cell biology, metabolic, genetic and cancer-induced bone diseases.
Honor and Awards: 2001: Travel grant, IBMS and ECTS joint Meeting; 2003: Novartis
Young Investigator Award, European Symposium on Calcified Tissues; 2004: Novartis Young
Investigator Award, European Symposium on Calcified Tissues; 2009: IBRA Robert Schenk
Research Prize.
Grants: 2003: Young Researcher Grant (FI-GI-RI), Department of Experimental Medicine,
University of L’Aquila; 2006: Novartis Research Agreement; 2011: 5th Research award
STRODER/SIOMMM, AIRC (Italian Association for Cancer Research) Investigator Grant;
2012: CARISPAQ Foundation.
Oral Presentations: 2003: European Symposium on Calcified Tissue, Rome, Italy;
International Conference in Bone and Mineral Research, Vien Austria; 2004: Frontiers of
Skeletal Biology, Davos, Switzerland; European Symposium on Calcified Tissue, Nice, France;
2005: European Symposium on Calcified Tissue, Geneve, Switzerland; 2006: European
Symposium on Calcified Tissue, Prague, Czech Republic; ASBMR 28th Annual Meeting,
Philadelphia, USA; International Conference on Progress in Bone and Mineral Research, Vien,
Austria; 2008: European Symposium on Calcified Tissue, Barcelona, Spain; 2009: 2nd IBMS
Davos Workshop: Bone Biology & Therapeutics, Davos, Switzerland; 2010: 9th Forum in Bone
and Mineral Research, Milan, Italy; 2011: 3rd Joint Meeting ECTS & IBMS, Athens, Greece;
ASBMR 33rd Annual Meeting, San Diego, USA; 2012: 2nd IOF-ESCEO pre-clinical
Symposium, Bordeaux, France; European Symposium on Calcified Tissue, Stockholm,
Sweden; ISSBB (Italian Society for Space Biomedicine and Biotechnology) VI National
Congress, Brindisi, Italy; CIBD (Cancer Induced Bone Diseases) meeting, Lyon, France;
AusBMR meeting, Vien, Austria;
Invited lectures: 2002: University of Brescia, Faculty of Pharmacology, Brescia, Italy; 2005:
Novartis Pharma, Basel, Switzerland; 2006: Mediterranean School of Oncology, Rome, Italy;
2007: Bone and Heart Meeting, Florence, Italy; 2009: 3rd IBRA (International Bone Research
Association) Scientific Seminar, Basel, Switzerland; 2010:
Istituto Tumori Giovanni
Paolo II, Bari, Italy; 2011: Osteotropic cancers: new pathogenic and clinical aspects, Bari, Italy;
SIOMMMS, XI National Congress, Rome, Italy; 2012: Policlinico Umberto I, Rome, Italy;
ECTS training workshop “Cancer and bone, a guide for in vivo experiments”, L’Aquila, Italy;
Editorial Duties/ Peer Review Panels: Reviewer: Acta Biomaterialia; Aging Clinical
Experimental Research; Archives Biochemistry and Biophysics; American J Physiology
Applied Physiology; Anticancer Therapy; Biologia; Biotech. Applied Biochem; BMC Cancer;
BMC Veterinary Research; Bone; British J Pharmacology; Clinical Cancer Research; Clinical
Experimental Metastasis; Clinical Investigation; Journal of Cell Biochemistry; Journal of
Endocrinology Investigation; Journal of Orthopaedic Research; Microgravity Science and
Technology
Grant Reviewer: NOW/SRON User Support Programme Space Research, the Netherlands.
Guest Editor: “Inflammation & Allergy – Drug Targets” special issue: “Bone and Immune
System cross-talk”.
Publications: 45 original research articles in peer-review international journals; 4 invited
chapters.
Pubblicazioni anni 2009-2013
1. Pierroz DD, Rufo A, Bianchi EN, Glatt V, Capulli M, Rucci N, Cavat F, Rizzoli R, Teti
A, Bouxsein ML, Ferrari SL. Beta-Arrestin2 regulates RANKL and ephrins gene expression in
response to bone remodeling in mice. J Bone Miner Res 24:775-784; 2009.
2. Taddei ML, Parri M, Angelucci A, Onnis B, Bianchini F, Giannoni E, Raugei G, Calorini
L, Rucci N, Teti A, Bologna M, Chiarugi P. Kinase-dependent and independent role of EphA2
in the regulation of prostate cancer invasion and metastasis. Am J Pathology 174:1492-1503;
2009.
3. Capulli M, Rufo A, Teti A, Rucci N. Global transcriptome analysis in mouse calvarial
osteoblasts highlights sets of genes regulated by modeled microgravity and identifies a
“mechanoresponsive ostoblast gene signature”. J Cell Biochem 107:240-252; 2009.
4. Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E, Capece D, Iansante
V, Zazzeroni F, Alesse E, Heinegård D, Teti A. The glycosaminoglycan-binding domain of
PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. J Cell
Biol 187:669-683; 2009.
5. Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V.
Receptor activator of NF-κB ligand enhances breast cancer–induced osteolytic lesions through
upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Research
70:6150-6160; 2010.
6. Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, Ferrari S, Pierroz D,
Morandi L, De Simone M, Rucci N, Bertini E, Bianchi ML, De Benedetti F, Teti A.
Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.
J Bone Miner Res. 2011
7. Peruzzi B, Cappariello A, Del Fattore A, Rucci N, De Benedetti F, Teti A. c-Src and IL-6
inhibit osteoblast differentiation and integrate IGFBP5 signalling. Nat Commun 3:630; 2012.
8. Cardone RA, Greco MR, Capulli M, Weinman EJ, Busco G, Bellizzi A, Casavola V,
Antelmi E, Ambruosi B, Dell'aquila ME, Paradiso A, Teti A, Rucci N, Reshkin SJ. NHERF1
acts as a molecular switch to program metastatic behavior and organotropism via its PDZ
domains. Mol Biol Cell. 23:2028-2040;2012.
9. Capulli M, Angelucci A, Driouch K, Garcia T, Clement-Lacroix P, Martella F, Ventura L,
Bologna M, Flamini S, Moreschini O, Lidereau R, Ricevuto E, Muraca M, Teti A, Rucci N.
Increased expression of a set of genes enriched in oxygen binding function discloses a
predisposition of breast cancer bone metastases to generate metastasis spread in multiple
organs. J Bone and Miner Res 27:2387-2398;2012.
10. Rucci N, Capulli M, Ventura L, Angelucci A, Peruzzi B, Tillgren V, Muraca M,
Heinegård D, Teti A. Proline/aRginine-rich End Leucine-rich repeat protein N-terminus is a
novel osteoclast antagonist that counteracts bone loss. J Bone Miner Res. 2013 Apr 4.